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electron capable machine in the largest cancer centers but to have 
most machines capable of treating electrons is wasteful and in the 
future unsustainable.  
 
 SYMPOSIUM: ADVANCE PRACTICE FOR RTT 
RESEARCH: THE GEOMETRIC UNCERTAINTIES CASE  
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implementation of national recommendations  
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Each country in the UK England, Scotland, Wales and Northern Ireland 
has its own health policy related to the development of services 
within the National Health Service (NHS).  This presentation focuses 
on work undertaken within England in relation to NHS Radiotherapy 
service provision.  
In England there are 50 NHS Radiotherapy providers, with 
radiotherapy services provided on 58 clinical sites.   The presentation 
will describe how a nationwide approach is helping support 
implementation of equitable high standards for patients across 
England.  
To enable this approach government established a National 
Radiotherapy Advisory Group to advise government ministers.  This 
group comprised professional representatives from each discipline, 
health care commissioners, patients and lay representatives and 
policy advisors from the Department of Health. The group made 
recommendations in the Report to Ministers in 2007 “Developing a 
world class Radiotherapy service for England” 1.   
The report made wide ranging recommendations about all aspects of 
service delivery including importantly standards of care related to 
technical service delivery.  A National Radiotherapy Implementation 
Group (NRIG) was established to oversee and support implementation 
of the recommendations2.  In 2011 the government set an ambitious 
goal to improve cancer patient’s outcomes, a national strategy 
Improving Outcomes: A strategy for cancer was published3.  This 
policy document built upon the radiotherapy NRAG recommendations 
and recommended an increase in capacity,  and implementation of 
the most up to date treatment technologies across England stating “ 
to improve outcomes from radiotherapy, there must be equitable 
access to high quality, safe, timely, protocol driven quality controlled 
services focused around patients’ needs”.   
This presentation focussing upon this work from 2007 to 2013, will 
describe the development of programmes and workstreams to support 
the implementation of the technical recommendations made within 
NRAG report.     
NB Specific details relating to the NRIG IGRT support programme will 
be provided by June Dean and Mark Elsworthy, National IGRT leads, 
Society of Radiographers and National Cancer Action Team in a paper 
within this session at ESTRO.  
1. NRAG (2007)  Radiotherapy: Developing a world class service for 
England , Report to Ministers from National Radiotherapy Advisory 
Group 26 February 2007. Accessed on line 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Pub
licationsPolicyAndGuidance/DH_074575  
2. Department of Health (2012) Radiotherapy Services in England 
2012.  Department of Health. London. Accessed on line 
https://www.wp.dh.gov.uk/publications/files/2012/11/Radiotherapy-
Services-in-England-2012.pdf 
 
3. Department of Health (2011) Improving Outcomes: A Strategy for 
Cancer. Department of Health. London. Accessed on line 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Pub
licationsPolicyAndGuidance/DH_123371  
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The employment of advanced image guidance techniques in clinical 
radiotherapy practice has ensured that geometrical uncertainties 
during treatment have been reduced. Hence, new techniques such as 
IMRT, and VMAT performed in a stereotactic setting can be applied 
safely with smaller margins.  
In our institute, the development of new radiotherapy (RT) techniques 
generally starts with retrospective studies on existing patient data. 
For example, to determine the required safety margin for a certain 
protocol, historic data will be analysed to determine organ motion, 
setup errors, and delineation variability in relation to the new 
protocol. To facilitate this, all patient imaging data are saved in 
databases and archived after patients have finished their treatment. 
Radiotherapy technicians (RTTs) often play an important role in 
collecting and managing these patient data, not only during treatment 
but also in its retrospective analysis.  
The collected data are analyzed by a research RTT, in close 
cooperation with a physicist and/or physician. This is followed by a 
proposal for introduction into the clinic, accompanied with a clinical 
implementation protocol. An IGRT implementation group, consisting 
of physicists, radiation oncologists and RTTs will guide and define the 
complete process from research to clinical implementation. After 
clinical implementation the newly developed technique is supervised 
by dedicated imaging RTTs until the technique is sufficiently 
imbedded in daily clinical practice. Once all other RTTs are 
sufficiently trained, the technique is fully implemented. During the 
whole process the technique will be evaluated and improvements can 
be made.   
To illustrate this procedure: We investigated the use of an optical 
imaging system (AlignRT) for monitoring the breath hold state of the 
patients during deep inspiration breath-hold RT. Data of 20 patients 
were collected and retrospectively analyzed to investigate geometric 
uncertainties such as inter-fraction, intra-fraction- and intra-beam 
variability. The results were used to evaluate the current kV guided 
breath-hold protocol and a number of adaptations were made as a 
result. 
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A report to ministers in 2007 by the national radiotherapy advisory 
group proposed a vision for future radiotherapy; that all new linear 
accelerators would be capable of 4D Adaptive Radiotherapy and this 
would become the standard of care in the future. 
A new document was required to support the wider adoption and 
application of image guided radiotherapy (IGRT) to enable the future 
implementation of 4D adaptive radiotherapy throughout England. 
The national implementation strategy proposed that IGRT support 
leads would be sent to each centre in England that requests support. 
The leads would be members of a multi-professional team consisting 
of oncologists, physicists and radiographers. 
Radiographers are providing on- site support in developing protocols, 
work instructions and training and reviewing current practice. Physics 
support is provided by 3 English centres and is an outreach service via 
e-mail or telephone. Oncologist support will be directed appropriately 
by the co-chair of the new IGRT guidelines group. 
The exit strategy of the IGRT Leads will be to generate a report on the 
current level of IGRT accessibility in England and a second for 
manufacturers regarding the functionality of the equipment with user 
feedback. 
Data will be presented regarding common themes of support provided. 
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The professional role of radiation therapy technologists (RTTs) has 
changed tremendously over the last two decades. This presentation 
will give a brief overview of these changes in the Netherlands, and 
discuss the training requirements to become an Advanced RTT 
Practitioner (AP) as well as some of the roles open to the AP in this 
country. A personal perspective is presented on studying for a 
Master’s degree that focused on image guidance for stereotactic spine 
radiotherapy alongside clinical work, and subsequently on combining 
research and clinical work in an academic medical centre.  
In order to become an AP, an RTT in the Netherlands is expected to 
undertake a Master’s degree in a relevant aspect of radiotherapy in 
addition to possessing the necessary clinical experience and personal 
attributes. Working with senior management to define their role, 
advanced RTT practitioners are increasingly active in professional 
training and education, research and development, and improving and 
delivering high-quality patient cancer care. They may take on 
extended clinical responsibilities in areas like image guidance and 
advanced treatment planning for example, perform some of the tasks 
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traditionally done by physicians or physicists and play an important 
role in the multidisciplinary implementation of new treatment 
techniques. There are now significant opportunities for RTTs to 
develop their role within the radiotherapy team, promote excellence 
in patient care and engage in research. 
 
 SYMPOSIUM: NORMAL TISSUE TOLERANCE: INDIVI-
DUALISED TREATMENT  
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Relationships between dose delivered to an organ at risk and 
radiation-induced complications have been studied for many years. 
Complications are often either dichotomised (present or not present) 
or coarsely graded using a 4-point scale. The three-dimensional dose 
distribution over a particular organ is also typically summarized using 
a simple mean dose, or as a dose-volume or dose-surface histogram 
(DVH or DSH). Thresholds, such as the volume receiving more than 
given dose (Vd) can be extracted from the histogram, or the 
histograms can be reduced further to a single number expressing 
normal tissue complication probability (NTCP).  
DVH reduction models have shown some success in predicting clinical 
outcomes, but all spatial dosimetric information is lost. For hollow 
organs, such as the rectum, models explicitly including the shape of 
dose distribution have been shown to provide stronger correlations 
with outcome than simple DSHs. Furthermore, different toxic end 
points have been shown to be associated with different features the 
dose distribution: rectal bleeding with lateral extent of the dose 
distribution and loose stools with longitudinal extent, whilst proctitis 
was associated most strongly with the DSHs itself. This indicates that, 
in addition to improving predictive power, the inclusion of spatial 
information in the NTCP model also has the potential to give insight 
into the mechanism behind various toxicities. The 2-dimensional DSH-
based models can also be extended consider the 3-dimensional dose 
distribution: dose tolateral and cranial component of parotid gland 
during head and neck radiotherapy has been shown to increase the 
risk of xerostomia. Interestingly, non-dosimetric factors were also 
included in this modelling and submandibular gland removal was 
shown to be an independent risk factor for xerostomia. 
The clinical severity of radiation-induced toxicity to a large “parallel” 
organ may depend on the baseline functional reserve. Lung perfusion 
SPECT or hyperpolarized gas ventilation MRI have been shown to be 
capable of mapping baseline lung function in lung cancer patients. 
Predictors of toxicity such as perfusion-weighted mean lung dose or 
perfusion-weighted DVHs can then be used to more accurately 
estimate the effects of treatment. These “functional DVHs” have been 
demonstrated to be useful for creating radiotherapy plans which 
preferentially avoid healthy, well-perfused lung. Similar approaches 
are also possible in the treatment of liver cancer, where it has been 
shown that maps of baseline function can be produced using dynamic 
contrast-enhanced CT, HIDA, GSA or mebrofenin SPECT and FDGal 
PET. 
In summary, the predictive power of traditional DVH reduction 
methods which summarize the 3D dose distribution in an organ at risk 
with a single number has been shown to be improved by adding 
additional information. Spatial dosimetric information has been shown 
to not only give stronger associations with treatment outcome, but 
also give insight into the mechanism behind various toxicities. 
Functional imaging can help assess functional reserve in parallel 
organs, allowing selective avoidance of healthy portions of damaged 
organs such as the liver and lungs and hybrid models incorporating 
dosimetric and non-dosimetric information have shown promise. To be 
useful in routine clinical practise implementation within commercial 
treatment planning systems and dose optimisation engines is required, 
together with more extensive validation against clinical outcome 
data. 
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The ability to predict individual risk of radiation-induced normal tissue 
complications is a long sought goal in radiobiology. During the last 
decade, substantial efforts have been made to establish a gene based 
predictive test for normal tissue radiosensitivity. Around 80 candidate 
gene studies have explored possible associations between SNPs and 
the risk of normal tissue complications after radiotherapy. Although 
around two-thirds of the studies reported significant associations, the 
results have been very inconsistent and independent confirmation of 
the associations rarely took place. In hindsight, it seems obvious that 
many of the studies published so far have suffered from severe 
methodological shortcomings of which insufficient statistical power 
and lack of correction for multiple testing are among the most 
prominent (1). 
After quite a teething period, substantial progress is currently being 
made in radiogenomic research. A number of important lessons have 
been learned from other research fields (2). There is a growing 
consensus that studies addressing SNPs need to be powered to detect 
rather small differences in toxicity risk. Two of the largest SNP studies 
ever conducted in normal tissue radiobiology, including more than 
1,600 and 2,000 patients, have recently been published (3,4) of which 
one actually reports a compelling association for a SNP near the TNF-
alpha gene. Cooperative research groups are increasingly active in the 
field. A large international meta-analysis addressing a TGF-beta1 SNP, 
comprising individual patient level data on 2,782 patients from 11 
cohorts, has been published (5). The first genome-wide association 
study in normal tissue radiobiology has been conducted and more are 
underway. These developments are certainly warranted and heraldt 
hat interesting discoveries will be made in the years to come. 
Nevertheless, the human genome has some fundamental 
characteristics that are challenging to deal with from a statistical 
point of view. Furthermore a number of clinical and dosimetrical 
issues need to be taken carefully into consideration in radiogenomic 
research (6). 
1) Andreassen. Searching for genetic determinants of normal tissue 
radiosensitivity--are we on the right track? Radiother Oncol 2010;97:1-
8. 
2) Andreassen et al. Will SNPs be useful predictors of normal tissue 
radiosensitivity in the future? Radiother oncol 2012;105:283-8. 
3) Barnett et al. Independent validation of genes and polymorphisms 
reported to be associated with radiation toxicity: a prospective 
analysis study. Lancet Oncol 2012;13:65-77. 
4) Talbot et al. A replicated association between polymorphisms near 
TNFalpha and risk for adverse reactions to radiotherapy. Br J Cancer 
2012;107:748-53. 
5) Barnett et al.Individual patient data meta-analysis shows no 
association between SNP rs1800469 in TGFB and late radiotherapy 
toxicity. Radiotherapy & Oncology 2012;105:289-95. 
6) Andreassen et al. Conducting radiogenomic research – do not forget 
careful consideration of the clinical data. Radiotherapy & Oncology 
2012;105:337-40. 
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Radiobiology and physics are closely coupled in considering the 
benefits versus the concerns of delivering brachytherapy, particularly 
as a boost in an already irradiated volume. Clearly, it is essential that 
the target volume is easily accessible to placement of intracavity 
applicators, catheters or seeds particularly if the brachytherapy is 
fractionated. Therefore brachytherapy tends to be most adopted as an 
alternative or additional modality to external beam delivery in the 
treatment of cancers in cervix, anus, rectum, head and neck, 
prostate, breast and skin. 
Since the source of radiation dose in brachytherapy is within the 
target volume, the dose fall-off outside the target volume is much 
more rapid compared with external beam treatment plans. For 
example comparing irradiation of prostate using high dose-rate 
brachytherapy with external beam plans, dose fall-off is 4–5 times 
greater with distance away from the organ in the brachytherapy. This 
more rapid dose fall-off outside the target volume also gives a major 
